RxDoctor Payments DataLook up a doctor →

Ari Geller, DO

Nephrology · Bloomfield, CTNPI 1710927892

Payments from drug & device makers

$525,890in general payments, 2019–2025

Across 490 payments — averaging $1073.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$136K
  • Akebia Therapeutics Inc$111K
  • Otsuka America Pharmaceutical, Inc.$81K
  • AstraZeneca$59K
  • Mallinckrodt Hospital Products Inc.$58K
  • Lilly USA, LLC$25K
  • plus $56K from 20 others

What the payments were for

  • Consulting fees$6,9133%
  • Speaking & faculty fees$185,18388%
  • Travel & lodging$9,4365%
  • Food & beverage$7,7884%
  • Education$1550%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$525,890 in reported general payments places this provider in the 95th percentile of 144 nephrology providers in Connecticut.

See all nephrology providers in Connecticut

Medicare billing

Part B allowed, 2024
$188,803
Medicare patients
382
Services billed
1,169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin159$119,760
FarxigaDapagliflozin Propanediol171$114,904
KerendiaFinerenone49$51,444
VeltassaPatiromer Calcium Sorbitex38$47,976
ClinolipidFat Emulsion/Olive/Soy/Phospho96$39,331
AuryxiaFerric Citrate22$32,969
Sevelamer Carbonate67$10,615
ProsolParenteral Amino Acid 20% No.148$7,785
DapagliflozinDapagliflozin Propanediol12$7,102
Torsemide137$2,912
Potassium Citrate ErPotassium Citrate38$2,299
Calcium Acetate21$1,832
Potassium Chloride32$1,632
Calcitriol81$1,588
Amlodipine Besylate171$1,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$11,585$119,760159 claims
AstraZenecaFarxiga$58,817$114,904171 claims
BayerKerendia$27$51,44449 claims
Akebia Therapeutics IncAuryxia$110,749$32,96922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 144 nephrology providers in Connecticut.

Other nephrology in Bloomfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →